SOUTH SAN FRANCISCO, Calif.,
Nov. 3, 2017 /PRNewswire/ -- Titan
Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing
proprietary therapeutics for the treatment of select chronic
diseases utilizing its ProNeura™ long-term, continuous drug
delivery technology, today announced that it will host a live
conference call at 4:15 p.m. EST /
1:15 p.m. PST on Thursday, Nov. 9, 2017 to discuss the company's
financial results as of Sept. 30,
2017. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beebe, Ph.D., executive vice president and
chief development officer; Brian
Crowley, vice president of finance; and Marc Rubin, M.D., executive chairman. A summary
of the third quarter financial results and other highlights will be
included in a press release to be issued prior to the call.
The live webcast of the call may be accessed by visiting the
Events page on Titan's website. The call can also be accessed by
dialing 1-855-940-9476 (or 1-412-317-5223 from outside the U.S.)
five minutes prior to the start time, and asking to be joined to
the Titan Pharmaceuticals call. An audio recording of the call will
also be archived on the Titan website.
About Titan Pharmaceuticals
Titan Pharmaceuticals Inc.
(NASDAQ:TTNP), based in South San
Francisco, CA, is developing proprietary therapeutics
primarily for the treatment of serious medical disorders. The
company's lead product is Probuphine®, a novel and long-acting
formulation of buprenorphine and the first and only commercialized
treatment of opioid dependence approved by the U.S. Food and Drug
Administration to provide continuous, around-the-clock blood levels
of buprenorphine for six months following a single procedure.
Probuphine employs Titan's proprietary drug delivery system
ProNeura™, which is capable of delivering sustained, consistent
levels of medication for three months or longer. Titan has granted
commercial rights in the U.S. and Canada for Probuphine to Braeburn
Pharmaceuticals. The ProNeura technology has the potential to be
used in developing products for treating other chronic conditions
such as Parkinson's disease and hypothyroidism, where maintaining
consistent, around-the-clock blood levels of medication may benefit
the patient and improve medical outcomes. For more information
about Titan, please visit www.titanpharm.com.
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
commercialization of Probuphine, the regulatory approval process,
the development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
CONTACT:
Titan Pharmaceuticals, Inc.:
Sunil Bhonsle, President
(650) 244-4990
Investors:
Stephen Kilmer
(650) 989-2215
skilmer@titanpharm.com
Media:
Susan Thomas
(650) 989-2216
sthomas@titanpharm.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-schedules-conference-call-to-review-third-quarter-2017-financial-results-300549485.html
SOURCE Titan Pharmaceuticals, Inc.